REG - Renalytix PLC - Grant of Share Options
06/07/2023 17:45
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230706:nRSF2612Fa&default-theme=true
RNS Number : 2612F Renalytix PLC 06 July 2023
Renalytix plc
("Renalytix" or the "Company")
Grant of Share Options
LONDON and SALT LAKE CITY - July 6, 2023 - Renalytix plc
(http://www.renalytix.com) (NASDAQ: RNLX) (LSE: RENX), the first company to
commercialize an FDA approved artificial intelligence (AI) enabled prognostic
blood test for individuals with Type 2 diabetes and chronic kidney disease,
announces that its Remuneration Committee have granted options over a total of
2,473,296 ordinary shares of 0.25 pence each in the capital of the Company
(the "Share Options") to the following individuals:
Name Position Options granted
James McCullough Chief Executive Officer 875,017
O. James Sterling Chief Financial Officer 575,160
Fergus Fleming Chief Technology Officer 352,902
Catherine Coste Non-Executive Director 190,000
The Share Options, which have been issued in line with the Company's existing
share option plan, have an exercise price of £1.025 per ordinary share, being
the closing price of the shares on the 5 July 2023.
All the Share Options bar those granted to Catherine Coste vest as follows:
one twelfth of the Share Options vest 3 months from the date of grant with one
twelth vesting quarterly after that, subject to the individuals remaining
employed by the Company.
The Share Options granted to Catherine Coste vest as follows: one third of the
Share Options vest 12 months from the date of grant with one eight vesting
quarterly after that, subject to Ms. Coste remaining a Non-Executive Director
of the Company.
The issue of the Share Options to James McCullough, Oliver Sterling, Fergus
Fleming, Thomas McLain and Catherine Coste are deemed to be related party
transactions pursuant to AIM Rule 13 of the AIM Rules for Companies. The
Company's directors (excluding those who are being awarded the Share Options)
consider, having consulted with the Nominated Adviser, Stifel Nicolaus Europe
Limited, that the terms of the related party transactions are fair and
reasonable insofar as the shareholders of the Company are concerned.
For further information, please contact:
Renalytix plc www.renalytix.com (http://www.renalytix.com)
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker) Tel: 020 7710 7600
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea
Investec Bank plc (Joint Broker) Tel: 020 7597 4000
Gary Clarence / Shalin Bhamra
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
(http://renalytix@walbrookpr.com)
Paul McManus / Lianne Applegarth / Alice Woodings Mob: 07980 541 893 / 07584 391 303 / 07407 804 654
CapComm Partners
Peter DeNardo Tel: 415-389-6400 or investors@renalytix.com (http://investors@renalytix.com)
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the
new field of bioprognosis™ for kidney health. The leadership team, with a
combined 200+ years of healthcare and in-vitro diagnostic experience, has
designed its KidneyIntelX technology platform to introduce novel laboratory
developed and FDA approved tests to enable risk assessment and appropriate
care management in adult patients with type 2 diabetes and early-stage CKD. By
gaining early visibility into risk for progressive decline in kidney function,
and an understanding of associated actionable insights, patients and health
care providers may benefit from improved outcomes and decreased costs. For
more information, visit our Company website at www.renalytix.com
(http://www.renalytix.com) and our product website at www.kidneyintelx.com
(http://www.kidneyintelx.com) .
About KidneyIntelX™
KidneyIntelX™ is a laboratory developed test demonstrated to be a reliable,
bioprognostic™ methodology that yields a simple-to-understand, custom risk
score, enabling prediction of which adult patients with T2D and early CKD
(stages 1-3) are at low, intermediate or high risk for rapid progressive
decline in kidney function. By combining information from KidneyIntelX with
newer cardio - and reno-protective therapies, doctors will have more
information in determining which patients are at higher versus lower risk for
rapid disease progression and may be able to more appropriately target
resources and guideline-recommended treatments to advance kidney health.
KidneyIntelX is supported by a growing body of clinical, utility and health
economic studies (including a validation study of two large cohorts) and has
demonstrated a 72% improvement in predicting those patients who are at high
risk for rapid progressive decline in kidney function versus the current
standard of care (eGFR and UACR). KidneyIntelX has received Breakthrough
Device Designation from the U.S. Food and Drug Administration and Renalytix
has submitted for De Novo marketing authorization. To learn more about
KidneyIntelX and review the evidence, visit www.kidneyintelx.com
(http://www.kidneyintelx.com) .
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name James McCullough
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Renalytix plc
b) LEI 213800NTOH3FK3WER551
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Options over ordinary shares of 0.25 pence each in the Company
Identification code GB00BYWL4Y04
b) Nature of the transaction Grant of options over shares
c) Price(s) and volume(s)
Price(s) Volume(s)
£1.025 875,017
d) Aggregated information
- Aggregated volume 875,017
- Price £896,892.43
e) Date of the transaction 6 July 2023
f) Place of the transaction Outside of trading venue - off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name O. James Sterling
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Renalytix plc
b) LEI 213800NTOH3FK3WER551
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Options over ordinary shares of 0.25 pence each in the Company
Identification code GB00BYWL4Y04
b) Nature of the transaction Grant of options over shares
c) Price(s) and volume(s)
Price(s) Volume(s)
£1.025 575,160
d) Aggregated information
- Aggregated volume 575,160
- Price £589,539
e) Date of the transaction 6 July 2023
f) Place of the transaction Outside of trading venue - off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Fergus Fleming
2 Reason for the notification
a) Position/status Chief Technology Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Renalytix plc
b) LEI 213800NTOH3FK3WER551
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Options over ordinary shares of 0.25 pence each in the Company
Identification code GB00BYWL4Y04
b) Nature of the transaction Grant of options over shares
c) Price(s) and volume(s)
Price(s) Volume(s)
£1.025 352,902
d) Aggregated information
- Aggregated volume 352,902
- Price £361,724.55
e) Date of the transaction 6 July 2023
f) Place of the transaction Outside of trading venue - off market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Catherine Coste
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Renalytix plc
b) LEI 213800NTOH3FK3WER551
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Options over ordinary shares of 0.25 pence each in the Company
Identification code GB00BYWL4Y04
b) Nature of the transaction Grant of options over shares
c) Price(s) and volume(s)
Price(s) Volume(s)
£1.025 190,000
d) Aggregated information
- Aggregated volume 190,000
- Price £194,750
e) Date of the transaction 6 July 2023
f) Place of the transaction Outside of trading venue - off market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHQQLFBXDLXBBERecent news on Renalytix
See all newsREG - Renalytix PLC - Holding(s) in Company
AnnouncementREG - Renalytix PLC - Holding(s) in Company
AnnouncementREG - Renalytix PLC - Holding(s) in Company
AnnouncementREG - Renalytix PLC - Holding(s) in Company
AnnouncementREG - Renalytix PLC - Late Breaking KidneyIntelX data show care impact
Announcement